{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T02:03:58Z","timestamp":1783649038897,"version":"3.55.0"},"reference-count":17,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2020.27110","type":"journal-article","created":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T17:50:41Z","timestamp":1606845041000},"page":"e2027110","source":"Crossref","is-referenced-by-count":24,"title":["Assessment of Cancer Therapy Evaluation Program Advocacy and Inclusion Rates of People Living With HIV in Anti\u2013PD1\/PDL1 Clinical Trials"],"prefix":"10.1001","volume":"3","author":[{"given":"Joshua E.","family":"Reuss","sequence":"first","affiliation":[{"name":"Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Stern","sequence":"additional","affiliation":[{"name":"Yale New Haven Health System, Bridgeport, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared C.","family":"Foster","sequence":"additional","affiliation":[{"name":"Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramya","family":"Ramaswami","sequence":"additional","affiliation":[{"name":"HIV\/AIDS Malignancy Branch, National Cancer Institute, Center for Cancer Research, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Lurain","sequence":"additional","affiliation":[{"name":"HIV\/AIDS Malignancy Branch, National Cancer Institute, Center for Cancer Research, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen X.","family":"Chen","sequence":"additional","affiliation":[{"name":"Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Streicher","sequence":"additional","affiliation":[{"name":"Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravie","family":"Kem","sequence":"additional","affiliation":[{"name":"Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard F.","family":"Little","sequence":"additional","affiliation":[{"name":"Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Sharon","sequence":"additional","affiliation":[{"name":"Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2020,12,1]]},"reference":[{"issue":"12","key":"zoi200874r1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081355","article-title":"Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada.","volume":"8","author":"Samji","year":"2013","journal-title":"PLoS One"},{"issue":"12","key":"zoi200874r2","doi-asserted-by":"publisher","first-page":"866","DOI":"10.7326\/M17-2499","article-title":"Projected cancer incidence rates and burden of incident cancer cases in HIV-infected adults in the United States through 2030.","volume":"168","author":"Shiels","year":"2018","journal-title":"Ann Intern Med"},{"issue":"7","key":"zoi200874r3","doi-asserted-by":"publisher","first-page":"507","DOI":"10.7326\/M14-2768","article-title":"Cumulative incidence of cancer among persons with HIV in North America: a cohort study.","volume":"163","author":"Silverberg","year":"2015","journal-title":"Ann Intern Med"},{"issue":"11","key":"zoi200874r4","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1001\/jamainternmed.2017.4349","article-title":"Lung cancer mortality associated with smoking and smoking cessation among people living with HIV in the United States.","volume":"177","author":"Reddy","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"26","key":"zoi200874r5","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi200874r6","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma.","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"issue":"33","key":"zoi200874r7","doi-asserted-by":"publisher","first-page":"3774","DOI":"10.1200\/JCO.2017.73.7338","article-title":"Modernizing clinical trial eligibility criteria: recommendations of the American Society of Clinical Oncology-Friends of Cancer Research HIV Working Group.","volume":"35","author":"Uldrick","year":"2017","journal-title":"J Clin Oncol"},{"issue":"9","key":"zoi200874r9","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1097\/ACM.0000000000000388","article-title":"Standards for reporting qualitative research: a synthesis of recommendations.","volume":"89","author":"O\u2019Brien","year":"2014","journal-title":"Acad Med"},{"issue":"11","key":"zoi200874r10","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.14816","article-title":"Characteristics of immune checkpoint inhibitors trials associated with inclusion of patients with HIV: a systematic review and meta-analysis.","volume":"2","author":"Sorotsky","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"475","key":"zoi200874r11","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat2702","article-title":"Tuberculosis following PD-1 blockade for cancer immunotherapy.","volume":"11","author":"Barber","year":"2019","journal-title":"Sci Transl Med"},{"key":"zoi200874r12","doi-asserted-by":"publisher","first-page":"644","DOI":"10.3389\/fimmu.2015.00644","article-title":"Dynamic perturbations of the T-cell receptor repertoire in chronic HIV infection and following antiretroviral therapy.","volume":"6","author":"Heather","year":"2016","journal-title":"Front Immunol"},{"issue":"7","key":"zoi200874r13","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1001\/jamaoncol.2018.6737","article-title":"Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: a systematic review.","volume":"5","author":"Cook","year":"2019","journal-title":"JAMA Oncol"},{"issue":"1","key":"zoi200874r14","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/s40425-019-0771-1","article-title":"Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection.","volume":"7","author":"Shah","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"7","key":"zoi200874r15","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1001\/jamaoncol.2020.0465","article-title":"Assessment of the feasibility and safety of durvalumab for treatment of solid tumors in patients with HIV-1 infection: the phase 2 DURVAST study.","volume":"6","author":"Gonzalez-Cao","year":"2020","journal-title":"JAMA Oncol"},{"issue":"9","key":"zoi200874r16","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1001\/jamaoncol.2019.2244","article-title":"Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer: a phase 1 study.","volume":"5","author":"Uldrick","year":"2019","journal-title":"JAMA Oncol"},{"issue":"22","key":"zoi200874r17","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1200\/JCO.2013.54.8644","article-title":"Cancer treatment disparities in HIV-infected individuals in the United States.","volume":"32","author":"Suneja","year":"2014","journal-title":"J Clin Oncol"},{"key":"zoi200874r8","unstructured":"NCI Division of Cancer Treatment & Diagnosis. Inclusion\/exclusion criteria for National Cancer Institute (NCI) sponsored clinical trials. Published September 4, 2018. Accessed September 1, 2020. https:\/\/ctep.cancer.gov\/protocolDevelopment\/docs\/NCI_ASCO_Friends_Eligibility_Criteria.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2773341\/reuss_2020_oi_200874_1606759118.41551.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T19:40:45Z","timestamp":1669923645000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2773341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,1]]},"references-count":17,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.27110","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,1]]}}}